Intra-Cellular Therapies (NASDAQ:ITCI) Rating Reiterated by Cantor Fitzgerald

Intra-Cellular Therapies (NASDAQ:ITCI)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $130.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 70.18% from the stock’s current price.

A number of other research analysts also recently commented on the stock. Royal Bank of Canada dropped their target price on shares of Intra-Cellular Therapies from $107.00 to $106.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. The Goldman Sachs Group cut their target price on Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Mizuho upped their target price on Intra-Cellular Therapies from $96.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, June 21st. Canaccord Genuity Group raised their price target on Intra-Cellular Therapies from $107.00 to $113.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $100.00 price objective on shares of Intra-Cellular Therapies in a research note on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $96.58.

Intra-Cellular Therapies Trading Up 1.3 %

NASDAQ:ITCI traded up $1.01 during trading hours on Monday, hitting $76.39. The company’s stock had a trading volume of 141,821 shares, compared to its average volume of 929,791. Intra-Cellular Therapies has a 52-week low of $45.50 and a 52-week high of $84.89. The stock has a market capitalization of $8.07 billion, a P/E ratio of -65.85 and a beta of 1.00. The stock has a fifty day moving average of $75.66 and a 200-day moving average of $71.24.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.03. The business had revenue of $161.40 million for the quarter, compared to analyst estimates of $157.74 million. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The business’s quarterly revenue was up 45.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.45) EPS. On average, sell-side analysts forecast that Intra-Cellular Therapies will post -0.59 earnings per share for the current year.

Insider Activity

In other news, CEO Sharon Mates sold 53,013 shares of the business’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total value of $4,010,433.45. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $80,970,388.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CEO Sharon Mates sold 53,013 shares of the stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $80,970,388.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Nostrand Robert L. Van sold 20,000 shares of the stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $75.91, for a total transaction of $1,518,200.00. Following the transaction, the director now owns 9,690 shares in the company, valued at $735,567.90. The disclosure for this sale can be found here. Insiders have sold 199,778 shares of company stock worth $14,892,738 over the last ninety days. 3.40% of the stock is currently owned by insiders.

Institutional Trading of Intra-Cellular Therapies

A number of institutional investors have recently modified their holdings of the company. Kapitalo Investimentos Ltda purchased a new stake in Intra-Cellular Therapies during the fourth quarter worth approximately $26,000. Headlands Technologies LLC purchased a new stake in shares of Intra-Cellular Therapies during the 1st quarter valued at about $32,000. Fidelis Capital Partners LLC purchased a new stake in shares of Intra-Cellular Therapies during the first quarter valued at approximately $53,000. Summit Securities Group LLC purchased a new stake in Intra-Cellular Therapies during the 2nd quarter worth $56,000. Finally, Cape Investment Advisory Inc. acquired a new position in Intra-Cellular Therapies in the 4th quarter worth $78,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.